Beyond the Steroid Epidural: PRP as a Regenerative Alternative for Spinal Pain

The epidural steroid injection has been the workhorse of interventional spine practice for the better part of three decades. For radicular pain from a lumbar disc, it remains the default — and for good reason. It works, it’s covered by most insurers, and the technique is well-established. But “default” and “best” are not the same thing, and the evidence has shifted enough over the last few years that the conversation with patients deserves to shift with it.

This article walks through where epidural corticosteroids genuinely help, where they fall short, and what the most recent randomised evidence — including three meta-analyses published in 2025 — now tells us about platelet-rich plasma (PRP) as an alternative.

What steroids actually do — and don’t do

Epidural corticosteroids are powerful anti-inflammatories. By suppressing phospholipase A₂, COX-2, and the downstream cytokine cascade around an irritated nerve root, they can produce rapid, dramatic pain relief. The 2024 Zhang meta-analysis of 17 RCTs confirmed clinically meaningful pain reduction at six weeks, and a separate analysis showed effectiveness out to six months in some patient subsets.

The honest reading of that literature, however, is more nuanced than the marketing. The same meta-analyses repeatedly show that steroid epidurals reduce pain without consistently improving function. They buy time. They do not heal anything. The American Society of Interventional Pain Physicians (ASIPP) places the evidence at Level 1 only for disc herniation with radiculitis; for spinal stenosis, discogenic pain, and post-surgical syndrome, the evidence sits at Level 2–4.

There are three further problems worth naming directly:

1. Diminishing returns. A 2025 meta-analysis by Ermawan and colleagues, pooling three RCTs of epidural steroid versus PRP for prolapsed lumbar disc, found that pain scores in the steroid group were significantly lower at one month — but then significantly worsened between months one and three (p=0.001) and between months three and six (p=0.003). The Oswestry Disability Index followed the same trajectory. Steroids gave fast relief and then rebounded. PRP, in the same analysis, showed gradual, sustained improvement across all three time points.

2. Systemic effects that are easy to underestimate. A single epidural dose suppresses the HPA axis for two to four weeks at typical doses, and a series of three injections can suppress it for up to three months. Innate and adaptive immunity are both impaired during this window — relevant for older patients, diabetics, and anyone in influenza or COVID season. Bone loss, hyperglycaemia, and electrolyte disturbance are dose-dependent and cumulative when patients receive injections from multiple providers across multiple years.

3. Rare but serious neurological events. The FDA Medicare review by Eworuke and colleagues (2021) documented 90 serious and sometimes fatal neurological events reported between 1997 and 2014 — paraplegia, quadriplegia, spinal cord infarction, stroke. Many were technique-related: epidural haematoma, direct cord injury, embolic infarction following inadvertent intra-arterial injection of particulate steroid. The absolute risk per injection is low, but the consequences are catastrophic, and the FDA’s 2014 black-box warning has not been retracted.

None of this argues for abandoning the steroid epidural. It argues for putting it in proper context — a short-term anti-inflammatory tool with a non-trivial safety profile and no regenerative effect — and for asking what else we have.

The case for PRP in the epidural space

Platelet-rich plasma is a concentrated, autologous preparation of the patient’s own platelets in plasma. Once activated, platelets release a cocktail of growth factors — PDGF, TGF-β1, VEGF, IGF, EGF — and bioactive proteins including IL-1 receptor antagonist (IL-1Ra), which directly antagonises one of the principal inflammatory mediators implicated in radicular pain.

Mechanistically, this gives PRP two distinct effects in the epidural space:

• An anti-inflammatory effect that overlaps with what steroids achieve, but without HPA-axis suppression or immunosuppression.
• A reparative effect — modulation of Schwann cell behaviour, axonal regeneration, micro-vascular protection through the IGF-1/PI3K/Akt pathway, and partial remodelling of the annulus and surrounding ligamentous tissue.

In other words, PRP does not just quiet inflammation; it engages the tissue’s own healing programme. That is the mechanistic difference, and it matters for how we counsel patients about expected timelines.

What the 2025 evidence actually shows

Three meta-analyses published in 2025 give us the cleanest contemporary picture.

Muthu et al. (Experimental Biology and Medicine, 2025) pooled five RCTs comprising 310 patients with lumbar disc disease and radiculopathy. PRP delivered comparable pain relief, comparable functional improvement, and comparable overall health benefits to steroids — without an increased risk of adverse events. Their conclusion was that PRP represents a viable alternative that could reduce dependence on steroids.

Ermawan et al. (Spine Surgery and Related Research, 2025) pooled three RCTs of 132 patients with prolapsed lumbar disc. Steroids won at one month. PRP won at six months for both pain (mean difference −1.51, 95% CI −1.98 to −1.05, p<0.00001) and ODI (mean difference −9.71, p=0.006). Critically, the steroid group showed significant deterioration over time; the PRP group did not. The authors concluded that PRP should be considered a stronger alternative for patients with disc prolapse.

Wang and Zhang (Journal of Orthopaedic Surgery and Research, 2025) pooled seven studies comprising 416 patients. Their finding was the most measured: steroids produced significantly better functional improvement at four weeks, but no significant difference between PRP and steroids at three or six months on either VAS or ODI. Adverse events were similar in incidence (1.7% PRP versus 2.6% steroid) but the PRP-related events were self-limiting — transient post-injection pain and short-lived weakness — whereas the steroid events included persistent pain.

These three reviews don’t agree on every detail, and the heterogeneity in PRP preparation across the included studies is a legitimate criticism. But they do agree on the core finding: PRP is at least non-inferior to steroids over the medium term, more durable in the longer term, and has a safety profile that is at worst equivalent and arguably better.

This is reinforced by individual studies of note. Centeno’s 2017 registry of 470 patients receiving epidural platelet lysate showed sustained pain and functional improvement at two years, with only 11 patients progressing to lumbar surgery. Wongjarupong’s 2023 RCT (30 patients, single-level HNP) showed PRP outperforming steroid at 6, 12, and 24 weeks for leg VAS. Playfair’s 2024 work using a higher-concentration leucocyte-poor PRP showed 91% patient satisfaction at one year for suspected discogenic pain.

The pattern is consistent. Steroids front-load. PRP back-loads. Patients deserve to know which curve they’re choosing.

Where PRP epidurals fit within a Functional Spine Unit framework

A persistent error in interventional spine medicine is treating the epidural as the entire conversation. Panjabi’s Functional Spine Unit (FSU) model has been around for thirty years and remains the most coherent way to think about why so many patients with “the same” disc lesion behave so differently — passive subsystem (disc, ligaments, facets), active subsystem (multifidi and the rest of the segmental stabilisers), and neural control system are interdependent. A radicular epidural that ignores Modic changes, multifidus atrophy, facet arthropathy, or sacroiliac contribution treats one subsystem and leaves the rest of the unit failing.

PRP epidurals fit naturally into this framework precisely because they are not single-target drugs. The same patient may benefit from a transforaminal PRP epidural, an intradiscal PRP, a multifidus injection, and a facet treatment — addressing each component of the failing FSU in a single session or staged sessions. Steroid pharmacology does not lend itself to this kind of multi-target approach because the cumulative steroid load becomes unsafe; PRP is autologous and dose-tolerant.

Who is — and who isn’t — a good candidate

PRP epidurals are most appropriate for patients with:

• Radicular pain from disc herniation, particularly when symptoms are sub-acute to chronic and the patient prefers to avoid steroids
• Discogenic pain with annular tears, high intensity zones, or Modic 1–2 changes
• Recurrent radicular pain who have already had one or more steroid epidurals with diminishing effect
• Diabetics, patients with osteoporosis, or those on immunosuppression where the systemic effects of steroid are problematic
• Patients who want a treatment compatible with active rehabilitation rather than a four- to six-week “rehab pause”

PRP is not the right tool for every situation. Acute cauda equina, progressive motor deficit, and infection or malignancy all need a different pathway. Severe central canal stenosis with neurogenic claudication is more often a surgical conversation than an injection one. And patients with pain primarily driven by mechanical instability need that addressed first, biologically or otherwise.

The practical bottom line

The honest summary, defensible from the 2025 literature, is this:

• For the first month, steroids are likely to give faster pain relief.
• By three to six months, PRP and steroids are comparable on pain, with PRP showing better functional and durability outcomes in two of three contemporary meta-analyses.
• Beyond six months, PRP’s regenerative mechanism gives it a clear edge in studies that follow patients out to one or two years.
• PRP carries no HPA-axis suppression, no immunosuppression, no accumulating bone or metabolic load, and a lower rate of clinically significant adverse events.
• PRP integrates with multi-target FSU-based management in a way steroids cannot.

That is enough, in my view, to reframe the default. The first-line conversation with a patient with radicular or discogenic pain should not be “steroid epidural now, biologic if it fails.” It should be a proper informed-consent discussion of both options, with the trajectory and trade-offs of each laid out honestly. For many patients, PRP will be the better starting point. For some — those who genuinely need rapid pain control above all else and accept the trade-offs — steroid still has a role, ideally at the lowest effective dose with non-particulate formulations.

The era when interventional spine medicine had only one tool is over. The evidence has caught up. Practice should follow.

References

1. Zhang J, Zhang R, Wang Y, Dang X. Efficacy of epidural steroid injection in the treatment of sciatica secondary to lumbar disc herniation: a systematic review and meta-analysis. Front Neurol. 2024;15:1406504. doi:10.3389/fneur.2024.1406504. PMID: 38841695.
2. Manchikanti L, Knezevic NN, Navani A, Christo PJ, Limerick G, Calodney AK, et al. Epidural interventions in the management of chronic spinal pain: American Society of Interventional Pain Physicians (ASIPP) comprehensive evidence-based guidelines. Pain Physician. 2021;24(S1):S27–S208. PMID: 33492918.
3. Ermawan R, Corrigan H, Fachreza MS, Mercy G, Angeline A, Jiwandono BS, et al. Epidural platelet-rich plasma long-term outcome is better than steroid for prolapsed lumbar intervertebral discs: a meta-analysis of randomized controlled trials. Spine Surg Relat Res. 2025;10(1):36–42. doi:10.22603/ssrr.2025-0007. PMID: 41695894.
4. Newton R, Kuitert LM, Slater DM, Adcock IM, Barnes PJ. Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. Life Sci.1997;60(1):67–78. doi:10.1016/S0024-3205(96)00590-5. PMID: 8995534.
5. Eworuke E, Crisafi L, Liao J, Akhtar S, Van Clief M, Racoosin JA, et al. Risk of serious spinal adverse events associated with epidural corticosteroid injections in the Medicare population. Reg Anesth Pain Med.2021;46(3):203–209. doi:10.1136/rapm-2020-101778. PMID: 33277405.
6. US Food and Drug Administration. FDA Drug Safety Communication: FDA requires label changes to warn of rare but serious neurologic problems after epidural corticosteroid injections for pain. Silver Spring, MD: US FDA; 23 April 2014. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-label-changes-warn-rare-serious-neurologic-problems-after
7. Muthu S, Viswanathan VK, Gangadaran P. Is platelet-rich plasma better than steroids as epidural drug of choice in lumbar disc disease with radiculopathy? Meta-analysis of randomized controlled trials. Exp Biol Med (Maywood). 2025;250:10390. doi:10.3389/ebm.2025.10390. PMCID: PMC11832311.
8. Wang X, Zhang Y. Therapeutic interventions of platelet-rich plasma versus corticosteroid injections for lumbar radicular pain: a systematic review and meta-analysis. J Orthop Surg Res. 2025;20(1):306. doi:10.1186/s13018-025-05725-z.
9. Centeno C, Markle J, Dodson E, Stemper I, Hyzy M, Williams C, et al. The use of lumbar epidural injection of platelet lysate for treatment of radicular pain. J Exp Orthop. 2017;4(1):38. doi:10.1186/s40634-017-0113-5. PMID: 29177632.
10. Wongjarupong A, Pairuchvej S, Laohapornsvan P, Kotheeranurak V, Jitpakdee K, Yeekian C, et al. “Platelet-rich plasma” epidural injection an emerging strategy in lumbar disc herniation: a randomized controlled trial. BMC Musculoskelet Disord. 2023;24(1):335. doi:10.1186/s12891-023-06429-3. PMID: 37118707.
11. Playfair D, Smith A, Burnham R. An evaluation of the effectiveness of platelet rich plasma epidural injections for low back pain suspected to be of disc origin — a pilot study with one-year follow-up. Interv Pain Med.2024;3(2):100403. doi:10.1016/j.inpm.2024.100403.
12. Panjabi MM. The stabilizing system of the spine. Part I. Function, dysfunction, adaptation, and enhancement. J Spinal Disord. 1992;5(4):383–389. doi:10.1097/00002517-199212000-00001. PMID: 1490034.
13. Panjabi MM. The stabilizing system of the spine. Part II. Neutral zone and instability hypothesis. J Spinal Disord. 1992;5(4):390–396. doi:10.1097/00002517-199212000-00002. PMID: 1490035.
14. Machado ES, Soares FP, Vianna de Abreu E, de Souza T, Meves R, Grohs H, et al. Systematic review of platelet-rich plasma for low back pain. Biomedicines. 2023;11(9):2404. doi:10.3390/biomedicines11092404. PMID: 37760845.